# Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients

> **NCT04080843** · PHASE2 · COMPLETED · sponsor: **Zhejiang University** · enrollment: 30 (actual)

## Conditions studied

- Colorectal Cancer
- RAS and BRAF Wild-type
- Colorectal Neoplasms
- Intestinal Neoplasms
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Neoplasms by Site
- Neoplasms
- Digestive System Diseases
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Rectal Diseases

## Interventions

- **DRUG:** Anlotinib Hydrochloride
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT04080843
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-15
- **Primary completion:** 2022-06-01
- **Final completion:** 2022-07-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-07-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04080843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04080843, "Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04080843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*